Cover Image
市場調查報告書

全球非何杰金氏淋巴瘤治療藥市場:成長,趨勢及預測(2017年∼2022年)

Global Non-Hodgkin Lymphoma Therapeutics Market - Segmented by Type of Treatment - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 603202
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球非何杰金氏淋巴瘤治療藥市場:成長,趨勢及預測(2017年∼2022年) Global Non-Hodgkin Lymphoma Therapeutics Market - Segmented by Type of Treatment - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 110 Pages
簡介

國立癌症研究所報告,2016年非何杰金氏淋巴瘤的新罹患數為7萬2580件,在非何杰金氏淋巴瘤起因的死亡案例是2萬150件。市場有強力的開發平台,不過,由於Rituximab的化療主導目前的市場,後期階段所使用的NHL治療藥暢銷流行。預計非何杰金氏淋巴瘤的治療所使用的Rituximab的銷售量拉抬這個市場成長。

本報告提供全球非何杰金氏淋巴瘤治療市場相關調查,市場概要,各治療類型、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 市場定義
  • 粒度分級單位
  • 基本貨幣
  • 期間的重新評估與預測
  • 一般調查的前提條件
  • 報告的說明

第2章 調查方法

  • 簡介
  • 分析方法論
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要推論

第5章 市場概要及產業趨勢

  • 目前市場方案
  • 市場概況
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 難治性/復發性疾病治療的未滿足需求
    • 有前途的開發平台
  • 市場阻礙因素
    • Rituximab反抗性非何杰金氏淋巴瘤的增加
    • 嚴格的法規指南
  • 市場機會
  • 主要課題

第7章 全球非何杰金氏淋巴瘤治療藥:市場區隔

  • 治療各類型
    • 化療
    • 免疫療法
    • 標靶治療
    • 放射線治療
    • 幹細胞移植

第8章 全球非何杰金氏淋巴瘤治療藥市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Roche
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Celgene
  • Millennium/Johnson-Johnson
  • Merck
  • Pharmacyclics/Janssen Biotech
  • Kyowa Hakko Kirin
  • CTI BioPharma
  • 其他

第11章 分析師對投資機會的見解

第12章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1547

Description

Non-Hodgkin Lymphoma Therapeutics Market

The global non-hodgkin lymphoma therapeutics market has been estimated to reach USD 7.45 billion in 2023. The market is expected to register a CAGR of 7.4% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.

Increase in public awareness about NHL and robust drug pipeline for the treatment of NHL

Increase in public awareness about NHL and robust drug pipeline for the treatment of NHL is driving the market. Improved diagnostic techniques to detect NHL is positively affecting the market. In addition, increase in prevalence of non hodgin lymphoma is also fuelling the NHL therapeutics market across the globe.

High cost of NHL drugs and side-effects associated with them

High cost of NHL drugs and various complications associated with it is acting as a restraint for non-hodgkin lymphoma therapeutics market. Additionally, increasing rituximab resistance, along with the stringent regulatory guidelines are restraining the growth of the market.

North America to dominate the market

The Non-Hodgkin Lymphoma Therapeutics market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.

North America dominates the non-hodgkin lymphoma therapeutics market due to the increasing technological advancements and the rising incidence of NHL in the country. Asia-Pacific is also expected to propel the non-hodgkin lymphoma therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing prevalence of NHL.

Key developments in the market

In August, 2017 Gilead Sciences, Inc. and Kite Pharma, Inc. announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $11.9 billion. Kite's most advanced therapy candidate, axicabtagene ciloleucel, is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma.

In November, 2017, U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) from AstraZeneca for treating adults who have an aggressive form of non-Hodgkin lymphoma called mantle cell lymphoma that has progressed despite at least one prior treatment.

Major key players: F. HOFFMAN LA-ROCHE LTD., JOHNSON & JOHNSON, MERCK, BRISTOL MYERS SQUIBB CO., CELGENE CORP, ELI LILLY AND CO., GLAXOSMITHKLINE PLC and BAYER AG etc.

Reasons to purchase this report

Market analysis for the Global Non-Hodgkin Lymphoma Therapeutics Market, with region-specific assessments and competition analysis on a global and regional scale.

Analyzing various perspectives of the company with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW

  • 5.1 CURRENT MARKET SCENARIO
  • 5.2 PORTER'S FIVE FORCES
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF CONSUMERS
    • 5.2.3 THREATS OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
    • 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1 MARKET DRIVERS
    • 6.1.1 INCREASING FOCUS ON PRECISION MEDICINE
    • 6.1.2 INCREASING INCIDENCE OF BRAIN CANCER
  • 6.2 MARKET RESTRAINTS
    • 6.2.1 VERY FEW BRAIN CANCER SPECIFIC DRUGS
    • 6.2.2 HIGH COST OF TREATMENT
  • 6.3 OPPORTUNITIES
  • 6.4 KEY CHALLENGES

7. MARKET SEGMENTATION

  • 7.1 BY CANCER TYPE
    • 7.1.1 GLIOMA
      • 7.1.1.1 ASTROCYTOMA
      • 7.1.1.2 OLIGODENDROGLIOMA
      • 7.1.1.3 EPENDYMOMA
      • 7.1.1.4 CHOROID PLEXUS PAPILLOMA
    • 7.1.2 MENINGIOMA
    • 7.1.3 PITUITARY ADENOMA
    • 7.1.4 SCHWANNOMAS
    • 7.1.5 MEDULLOBLASTOMA
  • 7.2 BY THERAPEUTICS
    • 7.2.1 RADIATION THERAPY
      • 7.2.1.1 X-RAY THERAPY
      • 7.2.1.2 GAMMA-RAY THERAPY
    • 7.2.2 CHEMOTHERAPY
      • 7.2.2.1 SYSTEMIC CHEMOTHERAPY
      • 7.2.2.2 LOCAL CHEMOTHERAPY
    • 7.2.3 TARGETED THERAPY
  • 7.3 BY GEOGRAPHY
    • 7.3.1 NORTH AMERICA
      • 7.3.1.1 US
      • 7.3.1.2 CANADA
      • 7.3.1.3 MEXICO
    • 7.3.2 EUROPE
      • 7.3.2.1 FRANCE
      • 7.3.2.2 UK
      • 7.3.2.3 GERMANY
      • 7.3.2.4 ITALY
      • 7.3.2.5 SPAIN
      • 7.3.2.6 REST OF EUROPE
    • 7.3.3 ASIA-PACIFIC
      • 7.3.3.1 INDIA
      • 7.3.3.2 CHINA
      • 7.3.3.3 JAPAN
      • 7.3.3.4 AUSTRALIA
      • 7.3.3.5 SOUTH KOREA
      • 7.3.3.6 REST OF APAC
    • 7.3.4 MIDDLE EAST AND AFRICA
      • 7.3.4.1 GCC
      • 7.3.4.2 SOUTH AFRICA
      • 7.3.4.3 REST OF MIDDLE EAST AND AFRICA
    • 7.3.5 SOUTH AMERICA
      • 7.3.5.1 BRAZIL
      • 7.3.5.2 ARGENTINA
      • 7.3.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE

  • 8.1 MERGERS AND ACQUISITIONS
  • 8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
  • 8.3 NEW PRODUCT LAUNCHES

9. KEY PLAYERS

  • 9.1 F. HOFFMAN LA-ROCHE LTD.
  • 9.2 PFIZER
  • 9.3 MERCK
  • 9.4 BRISTOL MYERS SQUIBB CO.
  • 9.5 NOVARTIS
  • 9.6 GLAXOSMITHKLINE PLC
  • 9.7 BAYER AG
  • 9.8 OTHERS

10. FUTURE OUTLOOK OF THE MARKET

Back to Top